

# The role of pre-receptor glucocorticoid metabolism in chronic inflammatory disease-associated muscle atrophy

Citation for published version (APA):

Webster, J. M. (2023). *The role of pre-receptor glucocorticoid metabolism in chronic inflammatory disease-associated muscle atrophy*. [Doctoral Thesis, Maastricht University, University of Birmingham]. Maastricht University. <https://doi.org/10.26481/dis.20230329jw>

**Document status and date:**

Published: 01/01/2023

**DOI:**

[10.26481/dis.20230329jw](https://doi.org/10.26481/dis.20230329jw)

**Document Version:**

Publisher's PDF, also known as Version of record

**Please check the document version of this publication:**

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

**Take down policy**

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

# Abstract

Chronic inflammatory diseases (CIDs) such as rheumatoid arthritis (RA) and chronic obstructive pulmonary disease (COPD) are associated with prolonged periods of local and systemic inflammation. As a result, patients with CIDs often encounter co-morbidities such as osteoporosis and skeletal muscle wasting. Glucocorticoids (GCs) are steroid hormones widely used in the treatment of CIDs due to their potent anti-inflammatory effects. Despite their efficacy, their clinical application is limited due to undesirable side effects including osteoporosis and muscle wasting. The enzyme 11 beta-hydroxysteroid dehydrogenase 1 (11 $\beta$ -HSD1) is found in abundance in tissues such as skeletal muscle and bone and converts inactive GCs to their active counterparts, increasing local GC activity. In this thesis we look at the contribution of 11 $\beta$ -HSD1 in mediating GC-induced muscle wasting in RA and acute exacerbations of COPD (AE-COPD). Using mouse models of RA and AE-COPD, we look at the impact global genetic deletion of 11 $\beta$ -HSD1 has in muscle and bone loss with inflammation or GC-excess. In emphysematous animals with pulmonary inflammation, genetic deletion of 11 $\beta$ -HSD1 resulted in exacerbated muscle atrophy in addition to increased corticosterone levels compared to wild-type (WT) controls. Mice with genetic overexpression of human TNF- $\alpha$  (TNF-tg) receiving corticosterone demonstrated a marked increase in muscle wasting compared to untreated mice. In contrast, a partial protection against muscle wasting was observed in 11 $\beta$ -HSD1 null mice with GC-treated polyarthritis. Taken together, our data suggest 11 $\beta$ -HSD1 inhibition in AE-COPD and RA may not protect against endogenous GC-driven muscle wasting, however when combined with therapeutic GCs, 11 $\beta$ -HSD1 inhibition may offer protection against muscle wasting in such disease settings.